Silver Book Fact

Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.

Black D, Thompson D, Bauer D, et al. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial. J Clin Endocrinol Metabo. 2000; 85(11): 4118-24. http://jcem.endojournals.org/cgi/content/full/85/11/4118

Reference

Title
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial
Publication
J Clin Endocrinol Metabo
Publication Date
2000
Authors
Black D, Thompson D, Bauer D, et al
Volume & Issue
Volume 85, Issue 11
Pages
4118-24
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • 30 drugs are currently in development for osteoporosis.